BioWorld

Dec. 26, 2002

View Archived Issues

Cephalon Filing Supplemental NDA For New Sleep Disorders

As generic competition looms for its narcolepsy tablet Provigil, Cephalon Inc. said it has filed a supplemental new drug application seeking a broadened label that would include other sleep and wakefulness disorders. (BioWorld Today) Read More

Merck Returns To Isis Rights To Preclinical Antisense Drug

Read More

Mice Teach Geneticists Strategies For Exploiting Circadian Rhythms In Treating Modern Sleep Disorder

Read More

Beckman Coulter Buying SNPs Genotyping Assets From Orchid

Read More

Holiday Notice

BioWorld's offices were closed Tuesday and Wednesday for the holiday season, and no issues were published those days. Read More

Other News To Note

Read More

Appointments And Advancements

Read More

U.S. Patent Disclosures

Read More